ImmuCell is an animal health company. Co. focuses on creating products that improve the health and productivity of dairy and beef cattle. The First Defense® product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. The target disease, calf scours (bovine enteritis), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. The First Defense® product line is an orally delivered scours preventive product on the market for calves with claims against E. coli, coronavirus and rotavirus. Co.'s Beyond Vaccination® marketing campaign focuses on providing antibodies without vaccination. The ICCC stock yearly return is shown above.
The yearly return on the ICCC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ICCC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|